Hormone therapy for the female performing artist

Research output: Contribution to journalReview articlepeer-review


This article reviews the benefits and risks of oral contraceptive (OC) use for the female performer during adolescence and her menstrual years and the use of hormone therapy (HT) during her menopausal and postmenopausal years. In adolescence, some of the adverse effects of menstruation may be prevented by the use of OCs. Newer products that allow less, frequent cycling afford some convenience in scheduling bleeding around performances. During the childbearing years, the use of OCs permits the performer to plan for children as she desires. While vocalists have been hesitant to use hormones, fearing changes in their voice quality, OC use seems to have no untoward effects and may actually improve voice parameters. More controversy and inconclusive evidence surround the use of HT during the menopausal and postmenopausal years. Currently, HT is indicated for three reasons only: (1) reduction of moderate to severe menopausal symptoms; (2) prevention of bone loss; and (3) treatment of vulvar and vaginal itching. It is important that the lowest possible doses be prescribed for patients in order to minimize the potential adverse effects of this therapy.

Original languageEnglish (US)
Pages (from-to)48-51
Number of pages4
JournalMedical Problems of Performing Artists
Issue number1
StatePublished - Mar 1 2005

ASJC Scopus subject areas

  • History and Philosophy of Science


Dive into the research topics of 'Hormone therapy for the female performing artist'. Together they form a unique fingerprint.

Cite this